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Developmental and Regenerative Biology, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, United StatesSummary Despite obvious differences between the multiple FLD etiolo-Induction of the unfolded protein response (UPR) is recognized as
central to fatty liver disease (FLD) pathophysiology. This pathway
may be a potential therapeutic target for FLD, as well as other dis-
eases. However, fundamental questions as to how UPR contrib-
utes to FLD remain unanswered. Conﬂicting data suggest that
this pathway can both protect against and augment this disease.
Here, we review the relationship between protein secretion,
endoplasmic reticulum function (ER), and UPR activation. The
UPR serves to maintain secretory pathway homeostasis by
enhancing the protein folding environment in the ER, and we
review data investigating the role for individual UPR players in
fatty liver (steatosis). We explore a novel concept in the ﬁeld that
all cases of UPR activation do not equal ‘‘ER stress’’. Rather, differ-
ent types of UPRs that can either protect against or cause FLD are
discussed. Reﬁning our current understanding of this complex
pathway is particularly important, as drugs that affect the protein
folding environment in the ER and affect UPR activation are being
successful in clinical trials for FLD.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Fatty liver disease (FLD) ranges from lipid accumulation in hepa-
tocytes (steatosis) to steatohepatitis, which can progress to ﬁbro-
sis, cirrhosis, and ultimately liver failure. Metabolic syndrome
and alcohol abuse are the most common causes of FLD, although
viral hepatitis, drug toxicity, and some metabolic disorders are
also culprits. Whether steatosis qualiﬁes as a bona ﬁde pathology
is under debate, but it is widely accepted that steatosis, which
may be a surrogate marker of increased free fatty acid inﬂux to
the liver, is the prerequisite step to disease progression. Thus,
FLD treatment begins with alleviating steatosis.Journal of Hepatology 20
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associated with serum protein deﬁciencies caused by a defect in
hepatocyte secretion. The cellular basis for this longstanding clin-
ical observation is not fully understood, however, there are sev-
eral clear measures indicating that FLD is associated with
suboptimal protein secretion by hepatocytes. This defect in the
secretory pathway can induce the unfolded protein response
(UPR), and UPR activation is observed in every FLD etiology [1].
Two possible hypotheses explain this ﬁnding: (i) lipid accumula-
tion in hepatocytes causes ER dysfunction and UPR activation,
and thus it is a consequence of steatosis or (ii) ER dysfunction
and unfolded protein accumulation precede steatosis, causing
the disease. Some studies support the ﬁrst theory – that lipotox-
icity can cause UPR activation [2] – however works from several
groups, including ours, have conclusively demonstrated that
accumulation of unfolded proteins in the ER is sufﬁcient to cause
steatosis [3–7]. This supports the second model that UPR activa-
tion causes steatosis. While this is likely true in some cases, this
model is oversimpliﬁed. Here, we provide an overview of the
UPR, summarize data supporting a role for the UPR in FLD, and
present the novel concept that there are different types of UPRs,
even a UPR continuum, with dramatically different outcomes in
FLD, which can explain the conﬂicting data in the ﬁeld. This excit-
ing idea lays the foundation to develop therapies that would
divert hepatocytes from a stressed, disease causing UPR to an
adaptive, beneﬁcial UPR.The unfolded protein response: three branches, many
outcomes
Secreted proteins begin their journey to the cell surface during
translation into the ER. There, proteins are glycosylated, folded,
and packaged into vesicles for transport to the Golgi apparatus
to become further modiﬁed and then targeted to their ﬁnal des-
tination. Hepatocytes carry out the essential function of secreting
serum proteins, including albumin, transferring, and clotting fac-
tors. Thus, when hepatocytes become diseased and the secretory
pathway is dysfunctional, serum protein deﬁciency occurs. The
clinical consequences of edema and hypocoagulation are frequent
complications of advanced liver disease.
The UPR functions in all cell types, but is most active in highly
secretory cells like hepatocytes. This pathway serves to both12 vol. 57 j 1147–1151
Golgi apparatus ER
Glycan
Nucleus
Translation
nATF6
EIF2AK3
EIF2A
P
P
XBP1
ATF4 mRNA
BIP, DNAJC3, GRP94,
PDI, EDEM1, DERL1,
CANX, CALR, DDIT3,
ATF6, XBP1, ATF4...
ATF6
ATF6
MBTPS1
MBTPS2
ATF4
ERN1
P
Unfolded
proteins
Folded
proteins
Splicing
XBP1 mRNA
XBP1s mRNA
BIP
XBP1
Fig. 1. The three branches of the UPR. Each of the most proximal UPR mediators receives an activating signal from the chaperone BIP or from unfolded proteins. Each
branch results in the activation of transcription factors that induce a set of genes (a partial list is provided) that then function to reduce the load of unfolded proteins in the
ER. This serves as a negative feedback to downregulate the UPR once homeostasis is achieved. p, phosphorylation.
Clinical Application of Basic Scienceenhance the protein folding capacity of the ER and the protein
quality control system that recycles or eliminates improperly
folded and thus potentially destructive secretory proteins. Thus,
the UPR is essential for hepatocyte homeostasis.
When there is an imbalance between the protein folding
capacity of the ER and the unfolded protein load, the UPR is fur-
ther upregulated to reduce the build up of secretory cargo in the
ER. It does this by decreasing the inﬂux of new proteins into the
ER, targeting terminally unfolded proteins for destruction and
inducing the transcription of hundreds of genes that serve to
expand the ER and alleviate the unfolded protein load in the ER
and restore homeostasis.
The three major UPR branches (Fig. 1) converge on the X-box
binding protein 1 (XBP1), activating transcription factor 4 (ATF4)
and ATF6 transcription factors that regulate hundreds of genes
that function to augment protein folding. One such category is
protein chaperones, which assist in protein folding. The major
ER chaperone – BIP – also serves as an unfolded protein sensor.
Thus, when unfolded proteins accumulate, they are bound by
BIP, releasing the three main UPR mediators that reside in the
ER membrane. EIF2AK3 (also called PERK) phosphorylates EIF2A
which blocks protein translation en masse while selectively pro-
moting translation of activating transcription factor 4 (ATF4)
mRNA. ERN1 splices XBP1mRNA to produce the active XBP1 tran-
scription factor. Third, ATF6 translocates to the Golgi apparatus1148 Journal of Hepatology 2012where it is cleaved by the MBTPS1 and MBTPS2 proteases to
release a fragment that can transit to the nucleus and act as a
transcription factor (nATF6). The UPR target genes include chap-
erones and other factors that serve to reduce the burden of
unfolded proteins in the ER as well as some of the major players
of the UPR. Once UPR function is ramped up, the unfolded protein
burden is reduced and this provides a negative feedback that
dials down the UPR.The UPR continuum: from homeostasis to apoptosis
The UPR has largely been studied in yeast or cultured mammalian
cells exposed to high doses of drugs that cause an acute and pro-
found accumulation of unfolded proteins in the ER. The result is
that each UPR branch and most target genes are induced. In this
experimental setting, the presence of the stressor is persistent,
resulting in an unrelenting accumulation of unfolded proteins
and signiﬁcant UPR activation. This is ER stress, and represents
the only one type of UPR. Other types of UPR have different, even
beneﬁcial functions.
While these in vitro studies have been useful in identifying
UPR target genes, this level of stress falls outside the physiologic
range experienced by most cells. Instead, there is a basal level of
UPR activity i.e., a homeostatic UPR, which can manage the loadvol. 57 j 1147–1151
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Fig. 2. The UPR as a stress-meter. There are multiple types of UPRs which can be
grouped into subclasses. The outcome can be dramatically different – a
homeostatic UPR maintains the efﬁcient processing of proteins through the
secretory pathway, an adaptive UPR occurs in cells that have recovered from a
moderate stress, a stressed UPR signals pathway dysfunction and correlates with
steatosis and a terminal UPR occurs when the stress is overwhelming and the cell
is eliminated by apoptosis. With the exception of a terminal UPR in which there is
a point of no return, the degree of UPR activation in a cell can ﬂuctuate, providing
the basis for treatment. A signature for each type of UPR has yet to be deﬁned.
JOURNAL OF HEPATOLOGYof cargo that fall within the physiological demands of hepato-
cytes in a healthy liver. However, if ER function is compromised,
unfolded proteins accumulate, and a stressed UPR ensues. This
induces all UPR branches and may not be unlike the stressed
UPR that occurs in experiments where cells are exposed to potent
stressors. Indeed, intraperitoneal injection of tunicamycin, a
potent UPR inducer, causes a stressed UPR in hepatocytes, fol-
lowed by steatosis [3,6–8]. Both ER stress and steatosis resolve
within 72 h in healthy animals because the full induction of the
stressed UPR effectively mitigates the transient accumulation of
unfolded proteins. Irreparable secretory pathway dysfunction,
however, can cause the stressed UPR to transition to a terminal
UPR, causing cell death. In contrast, if the UPR can manage the
unfolded protein burden, then homeostasis is restored, and, these
cells retain an enhanced ER protein folding capacity. This is anal-
ogous to the well-documented adaptive response to oxidative
stress following recovery, in which an enhanced antioxidant
capacity persists. When these adapted cells are re-stressed, UPR
induction is lower than in naïve cells.
We propose that the UPR serves as a stress meter for the
secretory pathway (Fig. 2). In this model, the UPR is not a single
entity, but is a continuum, where the constellation of activated
UPR mediators and effectors varies with the nature and duration
of the stress. Manipulation between UPR subclasses can serve as
the basis for treatments that will adjust the UPR dial. While there
are innumerable potential UPRs, grouping them into subclasses
(i.e., homeostatic, adaptive, stressed, and terminal) provides a
framework for understanding the markedly different outcomes
that result from each of them. Importantly, while a stressed
UPR may cause steatosis, recent ﬁndings have highlighted that
all UPRs do not. In contrast, an adaptive UPR protects against
FLD [3,9].UPR activation and FLD
An exciting advance has come from bridging the common clinical
observation of serum protein deﬁciency in patients with liver
disease to an underlying cellular and molecular mechanism thatJournal of Hepatology 2012gives rise to this disease, centered on the UPR. Thus, it is not sur-
prisingly to ﬁnd that ER dysfunction and UPR activation occur
with alcohol consumption and obesity [10–14], as well as with
steatosis in viral hepatitis [15,16] and even recovery of steatotic
allografts following liver transplant [17]. However, as the ﬁeld
matures to incorporate the nuanced and dynamic nature of this
pathway, important questions emerge. Namely, when some
markers of the UPR are detected in diseased livers, does it reﬂect
a stressed UPR that is contributing to the disease, or, conversely,
is it an adaptive UPR at work to restore hepatocyte function? This
remains an important issue to be addressed in future studies.
Recent studies have focused mainly on conventional genetic
approaches in mice to dissect the role of individual UPR players
in FLD. Results from these studies are conﬂicting (Table 1). For
instance, removing BIP from hepatocytes exacerbates FLD caused
by alcohol, high fat diet, and drugs [18], while overexpression of
BIP in hepatocytes alleviates FLD caused by obesity [19]. This
would suggest that BIP loss dials the UPR towards a stressed or
terminal UPR whereas BIP overexpression keeps the UPR dial in
the adaptive range. Interestingly, BIP heterozygotes are protected
from steatosis caused by a high fat diet [9]. This is attributed to
the partial loss of BIP resulting in a compensatory activation of
an adaptive UPR that renders hepatocytes resistant to the stress
induced by obesity.
Opposing results are found in other studies investigating the
main UPR players in FLD: blocking the ERN1–XBP1 branch by
deleting Ern1 in hepatocytes [8] or heterozygosity for Xbp1 [13]
worsens FLD, whereas deleting Xbp1 in hepatocytes makes them
more resistant to developing steatosis caused by a high carbohy-
drate diet [20]. We found that knock-down of Atf6 in zebraﬁsh
reduces steatosis incidence caused by chronic ER stress but
increases it in response to acute stress [3], similar to ﬁndings of
increased steatosis by tunicamycin injection in Atf6/ mice
[5,21]. Thus, loss of Atf6 has dramatically different effects
depending on the nature and duration of the stress. Data on the
EIF2AK3 pathway appears more straight forward in suggesting
that this pathway serves a protective function, as Eif2ak3/ mice
have increased steatosis [7], whereas keeping this pathway con-
stitutively active in hepatocytes is protective against the effects
of a high-fat diet [22].
Initial analysis of these studies presents a confusing picture.
For instance, when the stress is chronic, such as during obesity
or prolonged alcohol abuse, the effects of UPR depletion are dif-
ferent compared to an acute stress caused by binge drinking or
toxin exposure. Thus, it will be important for future studies on
UPR and FLD to analyze similar methods of depletion in parallel
with multiple FLD models.The UPR and lipids: what is the link?
Uncovering how this central aspect of the secretory pathway
impacts the hepatocyte metabolic machinery is a critical, unan-
swered question. Whether the UPR has a direct impact on lipid
metabolism remains to be determined. Compelling data suggests
that UPR activation drives hepatic insulin resistance [13], which
can then lead to lipogenesis. This is supported by the ﬁnding that
XBP1 drives expression of genes involved in triglyceride synthesis
[20]. However, in other studies, these genes were unaffected [3]
or decreased [5,21] in hepatocytes with ER stress, suggesting that
ER stress-induced steatosis does not require this pathway. Loss of
ATF6 has effects on expression of genes controlling b-oxidation ofvol. 57 j 1147–1151 1149
Table 1. Genetic manipulation of UPR mediators in mouse models of FLD alters insulin resistance and steatosis.
Target gene
[Ref.]
Genetic approach
(KO: knock-out; OE: overexpression; 
H: heterozygosity)
Fatty liver disease model Liver disease outcome
Global Hepatocyte
KO OE H KO OE H
Xbp1
[14]
X 17 wk high fat diet Hyperglycemia
Hyperinsulinemia
Glucose intolerance
Increased insulin resistance
Xbp1
[9]
X none Decreased plasma lipids
No change in steatosis
Decreased lipogenesis
Ern1
[25]
X 8, 24, 36, 48, 72 h post IP injection with tunicamycin Increased lipogenesis
UPR activation
Increased steatosis
Apoptosis
Atf6
[18,25]
X 8, 24, 48, 72 h post IP injection with tunicamycin Increased steatosis
Increased insulin resistance
Eif2ak3
[20]
X 6, 24, 36 h post IP injection with tunicamycin Apoptosis
Increased steatosis
Increased lipogenesis
Dnajc3
[18]
X 48 h post IP injection with tunicamycin Decreased lipogenesis
Increased steatosis
BiP
[24]
X 20 wk on high fat diet Hyperglycemia
Hyperinsulinemia
No steatosis
Increased insulin sensitivity
BiP
[6]
X 1. 6 wk high fat diet
2. 6-8 wk alcohol
Steatosis
Increased insulin resistance
Increased lipogenesis
Apoptosis
BiP
[7]
X Obese (ob/ob) mice 72 h post-injection of adenovirus 
expressing Bip
Decreased UPR activation
Decreased lipogenesis
Insulin sensitivity increased
Decreased gluconeogenesis
lnflammation
Clinical Application of Basic Sciencefatty acids [21], carbohydrate metabolism [5], and lipoprotein
export [21]. Whether any of these genes play a role in steatosis
following UPR induction remains to be determined.Summary and clinical perspective: treating fatty liver disease
by targeting the UPR
The ability for cells to transition between UPR subclasses has
important implications for treatment. We envision therapies that
would dial down a stressed UPR to become an adaptive one. The
successful treatment of FLD in rodent models and in humans with
chemical chaperones [23–25] is a clinical and scientiﬁc break-
through, which is rooted in this concept. This presents an exciting
new area for developing novel FLD treatments and also highlights
how basic research carried out without directives for transla-
tional relevance can provide novel, important insights into a
highly prevalent liver disease.Conﬂict of interest
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